0001144204-19-000512.txt : 20190103
0001144204-19-000512.hdr.sgml : 20190103
20190103203038
ACCESSION NUMBER: 0001144204-19-000512
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190101
FILED AS OF DATE: 20190103
DATE AS OF CHANGE: 20190103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REICHLING STEVEN
CENTRAL INDEX KEY: 0001556290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31822
FILM NUMBER: 19508119
MAIL ADDRESS:
STREET 1: 7000 NORTH BROADWAY, BUILDING 3-307
CITY: DENVER
STATE: CO
ZIP: 80221
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc
CENTRAL INDEX KEY: 0000727207
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 841072256
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3950 S. COUNTRY CLUB ROAD #470
STREET 2: BUILDING 3-307
CITY: TUCSON
STATE: AZ
ZIP: 85714
BUSINESS PHONE: 303-863-8088
MAIL ADDRESS:
STREET 1: 3950 S. COUNTRY CLUB ROAD #470
STREET 2: BUILDING 3-307
CITY: TUCSON
STATE: AZ
ZIP: 85714
FORMER COMPANY:
FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: HYDRO SEEK INC
DATE OF NAME CHANGE: 19880802
4
1
tv510264_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-01-01
0
0000727207
Accelerate Diagnostics, Inc
AXDX
0001556290
REICHLING STEVEN
C/O ACCELERATE DIAGNOSTICS, INC.
3950 S. COUNTRY CLUB ROAD, SUITE 470
TUCSON
AZ
85714
0
1
0
0
CHIEF FINANCIAL OFFICER
Employee Stock Option (right to buy)
11.50
2019-01-01
4
A
0
59830
0
A
2029-01-01
Common Stock
59830
59830
D
Employee Stock Option (right to buy)
11.50
2019-01-01
4
A
0
16604
3.31
A
2029-01-01
Common Stock
16604
16604
D
The options vest in four (4) equal annual installments on each anniversary of the date of grant beginning on January 1, 2021.
The options vest in twelve (12) equal monthly installments beginning on January 31, 2019.
The options were issued to the reporting person under the 2019 Salary Waiver and Nonqualified Stock Option Grant Plan (the "Sub-Plan") established pursuant to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan. Pursuant to the terms of the Sub-Plan, the reporting person irrevocably waived $55,000 of base compensation scheduled to be paid to the reporting person in 2019 in exchange for such options.
/s/ Steven Reichling
2019-01-03